Shuttle Pharmaceuticals Holdings Inc.

09/08/2025 | Press release | Distributed by Public on 09/08/2025 15:01

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 8, 2025, the Company's Board of Directors appointed Adam Chambers as a director of the Company.

There are no family relationships between Mr. Chambers and any of the Company's directors or executive officers. Mr. Chambers is the principal of Bowery Consulting Group Inc., which is the lender under the Company's revolving loan agreement, dated February 28, 2025. In addition, the Company and Bowery Consulting Group Inc. also entered into a consulting services agreement dated March 21, 2025. Other than that, Mr. Chambers does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There were no arrangements or understandings by which Mr. Chambers was appointed as a member of the Board of Directors.

Shuttle Pharmaceuticals Holdings Inc. published this content on September 08, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 08, 2025 at 21:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]